

Estimation of SLC25A3 Gene Expression in Chronic Myelogenous Leukemia Iraqi Patients

Raghda Raisan Al-Omairi, Maha Fakhry Al-Tae

Department of Biotechnology, College of Science, University of Baghdad, Baghdad, Iraq

Corresponding author: Raghda Raisan AL-Omairi, E.mail: raghdarayssan9216@gmail.com

Mobile: +9647714547679

ABSTRACT

Background: Chronic myelogenous leukemia is a malignant hematological disease of hematopoietic stem cells. It is difficult to adapt treatment to each patient's risk level because there are currently few clinical tests and no molecular diagnostics that may predict a patient's clock for the advancement of CML at the time of chronic phase diagnosis. Biomarkers that can differentiate people based on the outcome at diagnosis are needed for blast crisis prevention and response improvement.

Objective: This study is an effort to exploit the SLC25A3 gene as a potential biomarker for CML.

Methods: RT-qPCR was applied to assess the expression levels of the SLC25A3 gene.

Results: In comparison to the mean ΔC_t of the control group, which was found to be 0.409 ± 1.69 , the mean ΔC_t of CML patients was found to be 0.256 ± 2.7 ($p = 0.701$). Furthermore, when grouped by gender, there were no significant differences between CML patients and controls, whereas a significant difference was only detected when grouped by age. Additionally, the mean of gene expression folding of the SLC25A3 gene in CML patients was found to be 4.589 ± 8.552 which is >1 . Finally, no statistically significant link was discovered when the fold of expression was correlated with the age and gender of CML patients.

Conclusions: Gene expression folding ($2^{-\Delta\Delta C_t}$) was greater than 1 in CML patients which indicates that the gene could be used as a potential marker for the diagnosis, targeted therapy, and monitoring of prognosis in CML.

Keywords: CML (chronic myeloid leukemia), SLC25A3 (solute carrier family 25 member 3).

INTRODUCTION

15-20% of all adult leukemias are chronic myelogenous leukemia (CML), a malignant hematological disease of hematopoietic stem cells. In CML, cells are only partially developed, and these immature cells divide excessively and inefficiently. They build up in lymphoid tissues and peripheral blood, where they can cause anemia, thrombocytopenia, and leukopenia⁽¹⁾. With a median age of onset of 55 years, CML is more prevalent in older individuals. The majority of the time, there is no clear cause of CML, and there is a lack of information regarding its etiology, but exposure to high doses of radiation, whether accidental or therapeutic, as well as prolonged exposure to industrial chemicals like benzene, seem to be possible risk factors⁽²⁾.

Therefore, CML is a sporadic disease with no evidence of family history among monozygotic (identical) twins or close relatives of patients⁽³⁾. In CML, the bone marrow overproduces immature granulocytes, which then leak into the bloodstream. Additionally, the myeloblast percentage is less than 10%, and the proportions of neutrophils, monocytes, myelocytes, and eosinophils are higher than usual. The reciprocal chromosomal translocation $t(9;22)(q34;q11)$, which results in the Philadelphia chromosome, a tiny 22q- containing a BCR-ABL fusion gene expressing a BCR-ABL chimeric protein with dysregulated tyrosine kinase activity, is a significant cytogenetic feature of CML⁽⁴⁾.

The chronic phase, the acceleration phase, and the blast crisis phase are the three phases of CML. The acceleration and explosion crisis phases are only reached by a small percentage of patients in the chronic period. This may happen as a result of additional genetic

changes in leukemic stem cells that cytogenetic analysis can identify. The stage of the disease can be determined, and the best monitoring and therapy can be started by comparing laboratory data, including CBC, cytogenic, and molecular tests, which are used in the diagnosis of CML⁽⁵⁾. The solute carrier family 25member 3 gene (SLC25A3) has a molecular weight of 12,789 bases and is localized at 12q23. SLC25A3 is a gene that codes for a protein called Pic, which has a molecular weight of 40095 Da and a molecular size of 362 amino acids. By facilitating the movement of inorganic phosphate (Pi) into the mitochondrial matrix, this protein performs the dual roles of phosphate and copper transport, By way of exchanges with OH or symports with H⁺ in electroneutral transport. The availability of transport of copper can be regulated by phosphate levels, and SLC25A3 depletion or deletion lowers the overall mitochondrial copper levels necessary for cytochrome c oxidase production⁽⁶⁾.

Cancer cells have altered sensitivity to the mitochondrial and apoptotic pathways. Therefore, it is not surprising that a large number of mitochondrial carrier family members are engaged in the development of cancer. (PiC) controls the mitochondrial permeability transition pore's ability to release cytochrome c, and its suppression has anti-apoptotic effects⁽⁷⁾.

Cancer cells have considerably higher transmembrane potential than healthy cells do, and several of their transporters are changed. Drugs that target mitochondria have been developed as a result of these variations⁽⁸⁾.

Overexpression of this carrier activates the intrinsic apoptosis pathway, which has been shown in studies to have a potential function in mitochondria-dependent cell death⁽⁹⁾. Furthermore, disruption of ATP

production has been connected to phosphate carrier SLC25A3 deficiency ⁽¹⁰⁾. Our study aims to the estimation of SLC25A3 gene expression in CML patients and its possible implication as a biomarker for the disease.

MATERIALS AND METHODS

Blood Collection

The sample included 140 people who were split into two groups, healthy controls and people with chronic myelogenous leukemia. Eighty patient samples (49 male and 31 female) were gathered from the international hematology center in Baghdad, Iraq. The patient's ages ranged between 30 and 65. The 60 healthy samples, whose ages ranged from 30 to 50, were taken from volunteers at the international blood bank in Baghdad, Iraq (38 male, 22 female). A venipuncture was used to draw 2 milliliters of blood from each participant. For RT-qPCR analysis, the collected blood was immediately placed in the tubes containing TRIzolTM Reagent.

Ready to Use PCR Master Mix for cDNA Synthesis from Total RNA

TRIzolTM Reagent was used to isolate RNA from samples, and the synthesis of cDNA from RNA templates was performed using the Biorad thermocycler system/USA. The *AccuPower* RT PreMix is a master mix for cDNA synthesis consisting of an easy-to-resuspend, lyophilized mixture of *M-MLV* Reverse Transcriptase, RNase inhibitors, dNTPs, reaction buffer, tracking dye, and patented stabilizer. First-strand cDNA synthesis from RNA is accomplished using the master mix kit. Reverse transcription PCR is used for downstream applications (cDNA amplification). Only the template RNA, primers, and water were needed to initiate the reaction because all the necessary ingredients had been pre-mixed at the ideal concentrations, and the work was done following the manufacturing specifications.

The Protocol of cDNA Synthesis

- Template RNA and oligo-dT were mixed in a sterile tube as indicated in **Table 1**.
-

Table (1): Reaction volume and components of the used reverse transcription reaction used to prepare cDNA from total RNA.

Components		20 µl reaction
Template RNA	Total RNA	16 µl
Primer	Oligo dT18	2 µl
DEPC-DW		2 µl

- Synthesized cDNA was stored at -20°C or utilized immediately as a PCR template.

Primer's Design and Preparation

Using the NCBI gene bank database, the SLC25A3 gene's cDNA was sequenced along with a housekeeping gene termed GAPDH. RT-qPCR primers with melting

temperatures of 58 °C, lengths of 20–24 nucleotides, and PCR amplicon lengths of 155–185 base pairs were created using Prime software (Table 2). The working solution for GAPDH and SLC25A3 was created from lyophilized primers by dissolving them in nuclease-free water as directed by the manufacturer to create a stock solution containing 100 pmoles/µL of each primer, which was then kept at -23°C. A working solution with a concentration of 10 pmole/µL was obtained by diluting 10 µl of the primer stock solution with 90 µl of nuclease-free water, then stored at -23 °C until use.

Table 2: Primers sequences RT-qPCR

No.	primers		Sequences 5'→3'	Annealing Temp.
1	SLC25 A3	F	GGTTGCTCCTCTCTGGA TGA	58 °C
2	SLC25 A3	R	AACCTGCTACAAATGTT ACAACCA	58 °C
3	GAPD H	F	CCCACTCCTCCACCTTTG AC	58 °C
4	GAPD H	R	TTCCTCTTGTGCTCTTGC TG	58 °C

The Bioneer exicycler quantitative thermal block/Korea was used to identify and measure gene expression. *AccuPower*® *GreenStar*TM RT-qPCR master mix accurately detects target genes from a variety of samples. This real-time PCR reagent employs a dsDNA binding dye-based product that simultaneously evaluates fluorescence at each cycle to determine gene amplification. The kit has excellent detection and quantification capabilities for gene expression. The thermostable DNA polymerase, dNTPs, cofactors, and fluorescent dye are all included in this kit as one tube of lyophilized format (freeze-and-dried format). To proceed with real-time RT-PCR, only the template, primers, and nuclease-free distilled water are needed. The master mix was placed in a reaction vessel together with the template cDNA and the specific primers to initiate the reaction as shown in Table 3 and the work was done following the manufacturing specifications.

Table (3): Reagents of quantitative real-time PCR used in gene expression experiment

RT-PCR Reagents	
Components	Amount
2X Master Mix	1X
RT-PCR Forward-Primer (10 picomole/microliter)	1 µl
RT-PCR Reverse-Primer (10 picomole/microliter)	1 µl
Template cDNA	2 µl
Nuclease free water	16 µl
Total	20 µl

The reaction was conducted under **Table 4** listed conditions.

Table (4): RT-qPCR conditions.

Step	Condition	Duration	Cycle
Pre-Denaturation	95°C	3-5 min.	1
Denaturation	95°C	5-30 sec.	1
Annealing/Extension 40-45 /Detection	55-60°C	30-35 sec.	40-45

The threshold cycle (CT) for each sample was calculated using a real-time cycler program. The mean values were estimated after duplicate samples were tested. The $\Delta\Delta C_t$ method was used to normalize the expression data for SLC25A3 (the chosen gene) versus GAPDH (the housekeeping gene), and the findings were reported as fold changes in gene expression.

Statistical Analysis

Version 22 of SPSS for Windows was used to analyze the data (SPSS Inc. Chicago, Illinois, United States). Categorical variables were expressed using numbers and percentages, and Pearson Chi-square tests were used to see whether there were any significant differences. Parametric variables were given as mean \pm standard deviation (SD), and the least significant difference (LSD) test was used to determine whether there were any significant differences between the parametric variables. Interquartile range and median were used to express nonparametric variables (IQR). The Spearman rank-order correlation analysis was used to evaluate correlations between variables.

Ethical Approval

The Ministry of Environmental and Health and the Ministry of Higher Education and Scientific Research in Iraq both certified this research as being ethical.

RESULTS

Gender, Age and CML

338 cases of chronic myelogenous cancer were reported overall, according to the 2019 Iraq Annual Cancer Registry. Incidence and percentage were 0.94% and 0.86%, respectively. The National Center of Hematology in Baghdad, Iraq, provided the National Registry with all of its data.

Tables 5 and 6 show the findings for the CML patient group and the healthy control group according to gender and age. There was no statistically significant difference in the gender distribution of the CT and CML patient groups (males and females: 35% and 22.1% vs. 27.1% and 15.8%, respectively). The age range for CML patients was 30 to 65 years, whereas it was 30 to 50 years for healthy individuals. Patients with CML on average were older than those with CT (41.9 1.1 vs. 35.8 4.5 years old), and the difference was significant ($P < 0.001$).

Table (5): Frequencies of CML patients and controls depending on gender.

Groups	Gender	N (%)	P-value
Patients (N. =80)	Male	49 (35%)	0.8 NS
Controls (N. =60)	Male	38 (27.1%)	
Patients (N. =80)	Female	31 (22.1%)	
Controls (N. =60)	Female	22 (15.8%)	

NS: Non-Significant at the 0.01 level.

Table (6): Mean age parameters among CML patients and controls

Groups	Patients (N. =80) (mean \pm SD)	Controls (N. =60) (mean \pm SD)	p-value
Age (years)	41.9 \pm 1.1	35.8 \pm 4.5	<0.001**

**Significant at the 0.01 level.

Expression Level (ΔC_t) of SLC25A3 Gene

The mean ΔC_t of the SLC25A3 gene in CML patients was 0.256 \pm 2.7 compared to the mean ΔC_t of the control group which was determined to be 0.409 \pm 1.69, no significant difference was discovered ($p = 0.701$) between the two groups (**Table 7**). There were no significant differences between CML patients and controls when expression level (ΔC_t) was categorized by gender and age categories.

Table (7): Expression level (ΔC_t) of SLC25A3 gene in CML patients and controls. groups.

Gene expression Level (ΔC_t)	Patients (N. =80) (mean \pm SD)	Controls (N. =60) (mean \pm SD)	p-value
SLC25A3	0.256 \pm 2.7	0.409 \pm 1.69	0.701 NS

NS: Non-Significant.

Gene Expression Folding ($2^{-\Delta\Delta C_t}$) of SLC25A3

In this investigation, we discovered that the mean expression folding $2^{-\Delta\Delta C_t}$ of the SLC25A3 gene in CML patients was 4.589 \pm 8.552 (**Table 8**) which indicates that SLC25A3 could serve as a candidate biomarker for CML.

Table (8): The SLC25A3 gene expression folding $2^{-\Delta\Delta C_t}$.

Categories	No. of cases	Gene expression ($2^{-\Delta\Delta C_t}$) SLC25A3 (mean \pm SD)
CML	80	4.589 \pm 8.552

Correlation of Gene Expression Folding $2^{-\Delta\Delta C_t}$ of SLC25A3 Gene with Age in CML Patients

According to age, CML patients were split up into three groups in the current study.

- < 40 years (37 patients).
- 40 – 50 (27 patients).
- 50 years (16 patients).

In this investigation, we discovered that the mean expression folding $2^{-\Delta\Delta C_t}$ of the SLC25A3 gene in

CML patients was 5.135 ± 14.27 for ages under 40, 8.085 ± 17.97 for ages between 40 and 50, and 3.506 ± 8.08 for age over 50. Age group and SLC25A3 gene expression did not significantly correlate. According to **Table 9**, the correlation coefficients for the mean gene expression values of the SLC25A3 gene were 0.015, -0.231, and -0.043 for <40 years, 40-50 years, and >50 years, respectively. There was no discernible difference in terms of statistics.

Table (9): The SLC25A3 gene expression folding $2^{-\Delta\Delta Ct}$ correlation with age in the CML patients' group.

Age categories	Number of cases (N=80)	Gene expression ($2^{-\Delta\Delta Ct}$) SLC25A3 (mean± SD)	r	P-value
<40 years	37	5.135±14.27	0.015	0.932 ^{NS}
40-50 years	27	8.085±17.97	-0.231	0.245 ^{NS}
>50 years	16	3.506±8.08	-0.043	0.874 ^{NS}

NS: Non-Significant.

Correlation of Gene Expression Folding $2^{-\Delta\Delta Ct}$ of SLC25A3 Gene with Gender in CML Patients

As demonstrated in **Table 10**, there was no statistically significant difference in the mean gene expression folding $2^{-\Delta\Delta Ct}$ for the SLC25A3 gene in the female patient group and the male patient group (4.29 ± 8.31 vs. 4.72 ± 8.7 ; $p=0.828$, respectively).

Table (10): Correlation of The SLC25A3 gene expression folding $2^{-\Delta\Delta Ct}$ with gender in CML patients.

$2^{-\Delta\Delta Ct}$	Female group (N. =31) (mean± SD)	Male group (N. =49) (mean± SD)	P-value
SLC25A3	4.29 ± 8.31	4.72 ± 8.7	0.828 ^{NS}

NS: Non-Significant.

DISCUSSION

The high frequency of CML or the short life expectancy of elderly patients after diagnosis may be attributed to the low mean age at onset. Our findings support the study by **Ahmed et al.** which found that the mean age of CML patients in Iraq at diagnosis was 40.39 ± 14.30 which is younger than the globally reported age at initial diagnosis ⁽¹¹⁾.

In Asia, as opposed to Western populations, a lower age of onset between 38 and 40 years has been noted. According to **Gorre et al.** CML is extremely common among people between the ages of 20 and 40 (58.8%, with a mean age of 30.74 ± 6.10) and >40 (33.8%, with a mean age of 50.73 ± 7.50) ⁽¹²⁾. Altogether demonstrate that the majority of middle-aged individuals are more susceptible to getting CML. Additionally, a study by **Lin et al.** demonstrated that the incidence and death of CML in men were higher globally than those in women ⁽¹³⁾, however, the findings

from this study revealed that gender did not significantly affect incidence. The gender ratio (male to female ratio) in general observation differs throughout different geographic regions, as well as for various Asian countries, according to a study by **Gorre et al.** published in 2021 ⁽¹²⁾.

The predominance of men may be explained by their genetic makeup, innate immunological variations, hormone levels, potential occupational exposure to different types of radiation and toxins, nutrition, smoking, and drinking habits, as well as their genetics.

Inorganic phosphates are transported from the cytosol into the mitochondrial matrix via the mitochondrial phosphate carrier (PiC), which is encoded by the SLC25A3 gene. Copper availability and transportation can be regulated by phosphate levels. The overall amounts of mitochondrial copper are decreased by SLC25A3 deletion or depletion ⁽⁶⁾.

Cytochrome c is released from mitochondria via phosphate carriers, and its suppression had anti-apoptotic effects ^(14,15). In mouse hearts, SLC25A3 gene knockout somewhat desensitized mPTP to calcium-induced apoptosis but did not entirely prevent mPTP opening ⁽¹⁶⁾, these findings imply that phosphate carriers, like AAC and ATP-Mg/phosphate carriers, may play a role in mPTP opening and, consequently, carcinogenesis. Phosphate carrier activity was found to be increased in rat liver carcinoma ⁽¹⁷⁾, and SLC25A3 associated with several other genes was found to be differentially expressed in the early and late chronic phase of chronic myeloid leukemia ⁽¹⁸⁾. Because there are currently few clinical markers and no molecular tests that can predict an individual patient's clock for the progression of CML at the time of chronic phase diagnosis, it is challenging to tailor treatment to each patient's risk level ⁽¹⁹⁾.

The usual treatment for chronic phase chronic myeloid leukemia is a tyrosine kinase inhibitor, however, existing clinical scoring systems are unable to reliably predict the wide range of patient outcomes. To enhance care and make it easier for patients to join in clinical studies aimed at molecular level depth for blast crisis prevention and response improvement, biomarkers that can separate individuals based on the outcome at diagnosis are required. For clinical, biological, and technical reasons, it has been difficult to identify a small and manageable gene set that accurately predicts prognosis in the majority of CML patients ⁽²⁰⁾. The goal of this CML research will be the correlation of gene expression-based biomarkers with CML patients. The variability seen in our results considering expression levels of SLC25A3 (ΔCt) could be explained by what is typical of most carriers, which is that they exhibit both elevated and decreased transcriptional expression in a range of malignancies ⁽²¹⁾. We found that the fold changes of gene expression ($2^{-\Delta\Delta Ct}$) were greater than 1 which implicate that the SLC25A3 gene could be employed as a marker for CML. The simultaneous targeting of numerous carriers

offers a promising strategy that could considerably improve the efficacy and specificity of future cancer therapeutics, however, there is currently no research looking into the synergistic effects of different mitochondrial transporters.

Age is a significant risk factor for the emergence of numerous diseases, identification of genes whose expression changes with age has been important in discovering pathways whose behavior is altered by age, as well as in identifying aging biomarkers and therapeutic targets⁽²²⁾. These alterations may affect the degree to which genes are expressed, the splicing of the mRNA that is produced, or the genetic regulation of gene expression, several human genes have shown age-related changes in the heterogeneity of gene expression between people⁽²³⁾.

In a recent study, immunological T-cells from young and elderly people were compared, unstimulated cells showed no difference in cell-to-cell variability, but when the immune system was activated, the older cells showed increased heterogeneity⁽²⁴⁾. Our findings support the idea that greater variability in gene expression patterns is not always related to age. According to Medawar's theory, the power of purifying selection is stronger on genes expressed early in life compared to later in life, yet several highly proliferative tissues show the opposite tendency. High levels of malignancy and somatic mutations linked to the age of expression are present in these non-Medawarian tissues. Genes that are under genetic control, however, are subject to more lenient restrictions⁽²⁵⁾.

In **Whitney *et al.*** analysis of multiple sequential samples from the same individuals to identify donor-specific patterns of gene expression, a surprising and intriguing finding was the obvious negative association between Ig gene expression and donor age⁽²⁶⁾, which is consistent with the idea that age and genetic expression aren't always related. Furthermore, a study by **Yamamoto *et al.*** divided participants into six age bins ranging from 20 to 80 years old and compared the mean difference in gene expression distances between elderly and young people as well as the slope of the inter-individual JSD, they identified tissues with higher variability in both young and old populations with remarkably similar results, Pearson's $R = 0.8$ ⁽²⁵⁾. Thus, aging does not always lead to increasing variability in gene expression patterns, contrary to the initial hypothesis.

Human physiology, anatomy, and illness susceptibility vary significantly depending on gender. Disease characteristics including prevalence, progression, age of onset, and treatment response frequently vary by sex, and many immunological and inflammatory illnesses exhibit a startling gender bias in incidence and severity^(27,28). Different factors, including hormones, sex chromosomes, genotype-sex effects, behavioral differences, and environmental exposures, have been suggested as the causes of these sex disparities⁽²⁹⁾. Although the vast majority of prevalent

diseases show obvious sex differences in symptoms or prevalence, sex is typically neglected or improperly taken into account in studies⁽³⁰⁾.

Although differences in cancer incidence, susceptibility, and prognosis have been extensively characterized, it is unclear why these differences take place at the genetic level. Numerous malignancies exhibit differences in incidence and mortality rates linked to sex-specific disparities, some of these differences may be caused by various levels of hormones, particularly estrogen, or sexual chromosomal dosage⁽³¹⁾. With a few exceptions, such as thyroid cancer and lung cancer in nonsmokers, malignancies of the larynx, esophagus, and bladder, which have a male preponderance of 2:1 and 4:1 respectively, and typically have a bad prognosis, have been seen to occur more frequently in men than in women^(32,33). Mechanistic mathematical models of signaling activity were employed by **Çubuk *et al.*** to ascertain how gender-specific gene expression activities affect cell functionality and fate. In addition, the mechanistic modeling framework was used to mimic medication interventions and investigate how gender-specific variable gene expression affects drug action mechanisms, they found that some cancers, such as glioblastoma or rectum cancer, are almost insensitive to these gender-specific traits⁽³⁴⁾, as we discovered in our investigation into CML.

CONCLUSION

We concluded that the mean ΔCT of the SLC25A3 gene was variable when compared between patients and control (0.256 ± 2.7 , 0.409 ± 1.69 ; $p = 0.701$ ^{NS}), but the mean for gene expression folding $2^{-\Delta\Delta Ct}$ was greater than 1 in CML patients (4.589 ± 8.552) which indicates that the gene could be implicated as a marker for diagnosis or targeted for therapy in CML. Furthermore, we found that the gene expression wasn't statistically correlated with differences in age groups or gender of patients. We suggest further research into a subset of mitochondrial solute carrier genes in synergisty and studying its relationship with CML. Finally, patients with CML were seen to have an average age and median age at onset of 36.34 years and 35 years, respectively. These values were lower than the ones internationally reported.

Conflict of Interest

The authors declare that they have no conflict of interest.

REFERENCES

1. **Soverini S, Benedittis C, Mancini M *et al.* (2016):** Best practices in chronic myeloid leukemia monitoring and management. *The Oncologist*, 21(5):626-633.
2. **Aljoubory H, Altaee M (2021):** Correlation Study between three different genes expression and chronic myeloid leukemia in Iraq. *The Iraqi Journal of Agricultural Science*, 52(3):611-619.
3. **Chen Y, Wang H, Kantarjian H *et al.* (2013):** Trends in chronic myeloid leukemia incidence and survival in the

- United States from 1975 to 2009. *Leukemia & Lymphoma*, 54(7):1411-1417.
4. **Abdullah W, Maha F (2022):** Caspase 9 gene expression and caspase 9 protein in chronic myeloid leukemia in Iraq. *Iraqi Journal of Agricultural Sciences*, 53(5):994-1002.
 5. **Patologia S, Pediatria S, Associação B (2013):** Chronic myeloid leukemia. Elsevier, 59(3): 220-232
 6. **Boulet A, Vest K, Maynard M et al. (2018):** The mammalian phosphate carrier SLC25A3 is a mitochondrial copper transporter required for cytochrome c oxidase biogenesis. *Journal of Biological Chemistry*, 293(6):1887-1896.
 7. **Alcalá S, Klee M, Fernández J et al. (2008):** A high-throughput screening for mammalian cell death effectors identifies the mitochondrial phosphate carrier as a regulator of cytochrome c release. *Oncogene*, 27(1):44-54.
 8. **Zhang X, Zhang P (2016):** Mitochondria targeting nano agents in cancer therapeutics. *Oncology Letters*, 12(6):4887-4890.
 9. **Cléménçon B, Babot M, Trézéguet V (2013):** The mitochondrial ADP/ATP carrier (SLC25 family): pathological implications of its dysfunction. *Molecular Aspects of Medicine*, 34(2-3):485-493.
 10. **Mayr J, Zimmermann F, Horváth R et al. (2011):** Deficiency of the mitochondrial phosphate carrier presenting as myopathy and cardiomyopathy in a family with three affected children. *Neuromuscular Disorders*, 21(11):803-808.
 11. **Ahmed A, Khaleel K, Fadhel A et al. (2022):** Chronic myeloid leukemia: A retrospective study of clinical and pathological features. *Latin American Journal of Biotechnology and Life Sciences*, 7(3):41.
 12. **Gorre M, Sashidhar R, Annamaneni S et al. (2019):** Demographic and clinical characteristics of chronic myeloid leukemia patients: A study on confined populations of Southern India. *Indian Journal of Medical and Pediatric Oncology*, 40(01):70-76.
 13. **Lin Q, Mao L, Shao L et al. (2020):** Global, regional, and national burden of chronic myeloid leukemia, 1990–2017: a systematic analysis for the global burden of disease study 2017. *Frontiers in Oncology*, 10:580759.
 14. **Dai X, Zhang J, Arfuso F et al. (2015):** Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. *Experimental Biology and Medicine*, 240(6):760-773.
 15. **Cianciulli A, Porro C, Calvello R et al. (2018):** Resistance to apoptosis in *Leishmania infantum*-infected human macrophages: a critical role for anti-apoptotic Bcl-2 protein and cellular IAP1/2. *Clinical and Experimental Medicine*, 18(2):251-261.
 16. **Kwong J, Davis J, Baines C et al. (2014):** Genetic deletion of the mitochondrial phosphate carrier desensitizes the mitochondrial permeability transition pore and causes cardiomyopathy. *Cell Death & Differentiation*, 21(8):1209-1217.
 17. **Tkacova E, Kuzela S (1985):** Elevated phosphate transporting activity and phosphate carrier content in mitochondria of rat hepatoma with high glycolytic capacity. *Biochemistry International*, 11(1):45-50.
 18. **Oehler V, Yeung K, Choi Y et al. (2009):** The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. *The Journal of the American Society of Hematology*, 114(15):3292-3298.
 19. **Radich J, Dai H, Mao M et al. (2006):** Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proceedings of the National Academy of Sciences*, 103(8):2794-2799.
 20. **Krishnan V, Kim D, Hughes T et al. (2022):** Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. *Haematologica*, 107(2):358.
 21. **Lytovchenko O, Kunji E (2017):** Expression and putative role of mitochondrial transport proteins in cancer. *Bioenergetics*, 1858(8):641-654.
 22. **Glass D, Viñuela A, Davies M et al. (2013):** Gene expression changes with age in the skin, adipose tissue, blood, and brain. *Genome biology*, 14(7):1-12.
 23. **Viñuela A, Brown A, Buil A et al. (2018):** Age-dependent changes in mean and variance of gene expression across tissues in a twin cohort. *Human molecular genetics*, 27(4):732-741.
 24. **Martinez C, Eling N, Chen H et al. (2017):** Aging increases cell-to-cell transcriptional variability upon immune stimulation. *Science*, 355(6332):1433-1436.
 25. **Yamamoto R, Chung R, Vazquez J et al. (2022):** Tissue-specific impacts of aging and genetics on gene expression patterns in humans. *Nature communications*, 13(1):1-12.
 26. **Whitney A, Diehn M, Popper S et al. (2003):** Individuality and variation in gene expression patterns in human blood. *Proceedings of the National Academy of Sciences*, 100(4):1896-1901.
 27. **Kuan V, Denaxas S, Gonzalez A et al. (2019):** A chronological map of 308 physical and mental health conditions from 4 million individuals in the English National Health Service. *The Lancet Digital Health*, 1(2):e63-e77.
 28. **Westergaard D, Moseley P, Sørup F et al. (2019):** Population-wide analysis of differences in disease progression patterns in men and women. *Nature communications*, 10(1):1-14.
 29. **Khramtsova E, Davis L, Stranger B (2019):** The role of sex in the genomics of human complex traits. *Nature Reviews Genetics*, 20(3):173-190.
 30. **Ober C, Loisel D, Gilad Y (2008):** Sex-specific genetic architecture of human disease. *Nature Reviews Genetics*, 9(12):911-922.
 31. **Kim H, Lim H, Moon A (2018):** Sex differences in cancer: epidemiology, genetics and therapy. *Biomolecules & Therapeutics*, 26(4):335.
 32. **Costa A, Oliveira M, Cruz I et al. (2020):** The sex bias of cancer. *Trends in Endocrinology & Metabolism*, 31(10):785-799.
 33. **Mauvais F, Merz N, Barnes P et al. (2020):** Sex and gender: modifiers of health, disease, and medicine. *The Lancet*, 396(10250):565-582.
 34. **Çubuk C, Can F, Peña M et al. (2020):** Mechanistic models of signaling pathways reveal the drug action mechanisms behind gender-specific gene expression for cancer treatments. *Cells*, 9(7):1579.